Abstract: A temperature control device for temperature control of a steering device, characterized in that the temperature control device has at least one heat-conducting device, at least one thermoelectric device, and at least one fluid transport apparatus.

Abstract: A power-tool cooling apparatus for a portable power tool comprises at least one cooling unit configured to generate a cooling fluid flow to cool a drive unit of the portable power tool, and at least one further cooling unit configured to generate a further cooling fluid flow. The at least one further cooling unit is designed to differ from the at least one cooling unit.

Abstract: Systems and methods for resolving fault detection in a control system is provided. The system includes an I/O module operably connected to a first, second, and third microcontroller for transmitting data. The first microcontroller is in an active state, i.e., in control, while the remaining controllers are in an idle state. The system further includes an event generator for generating an event indicative of a fault occurrence, and a means for detecting a fault event. The system also includes a means for reassigning a controller, wherein upon detection of a fault event in both the first and second controllers, the means for reassigning a controller changes the state of the third controller to active, leaving the remaining controllers idle or in a shutdown state, thereby effectively assigning control from the first controller to the third controller.

Abstract: An insulin analog comprises a B-chain polypeptide containing a cyclohexanylalanine substitution at position B24 and optionally containing additional amino-acid substitutions at positions A8, B28, and/or B29. A proinsulin analog or single-chain insulin analog containing a B domain containing a cyclohexanylalanine substitution at position B24 and optionally containing additional amino-acid substitutions at positions A8, B28, and/or B29. The analog may be an analog of a mammalian insulin, such as human insulin. A nucleic acid encoding such an insulin analog is also provided. A method of lowering the blood sugar of a patient comprises administering a physiologically effective amount of the insulin analog or a physiologically acceptable salt thereof to a patient. A method of semi-synthesis using an unprotected octapeptide by means of modification of an endogenous tryptic site by non-standard amino-acid substitutions.

Abstract: A single-chain insulin comprises a C-domain of 6 to 11 amino acid residues comprising at least two acidic residues at the N-terminal side of the C-domain and at least two basic residues at the C-terminal side of the C-domain peptide, a basic amino acid residue at the position corresponding to A8 of human insulin, and an acidic amino acid residue at the position corresponding to A14 of human insulin. The C-domain may contain a 2 to 4 amino acid joint region between the acidic and basic residues. Residues C1 and C2 may have a net negative charge of ?1 or ?2; and the remaining C-domain segment may culminates with two basic residues. A pharmaceutical composition comprises the single-chain insulin, formulated at a pH within the range 7.0 to 8.0, and may be formulated at a concentration of 0.6 mM to 5.0 mM and/or at a strength of U-100 to U-1000.

Abstract: A sensing head (1) for a transducer for capturing rotation or linear parameters, of a rotatable or linearly movable component, in particular of a shaft (13), includes a housing (2), a first sensor unit (3) and a second sensor unit (5) arranged on the housing (2) and arranged in a circumferential direction (U) of the rotatable component offset in relation to each other. The first sensor unit has a first sensor surface (4) and the second sensor unit has a second sensor surface (6). Each of the sensor units (3, 5) can be rotated about a rotation axis (7, 30) such that the sensor surfaces (4, 6) are pivotable to each other in at least two different angular positions. The rotation axes (7, 30) of the sensor units (3, 5) are located on the sides (34, 36) of the sensor units (3, 5); forming the sensor surfaces (4, 6).

Abstract: The present invention provides rapid-acting insulin and insulin analogue formulations. The invention further provides delivery devices, particularly infusion sets, which allow for the rapid absorption of insulin and insulin analogues, as well as other active agents. Methods of using the insulin and insulin analogue formulations as well as the insulin delivery devices for treating subjects with diabetes mellitus are also provided.

Abstract: A hand-held power tool suction extractor apparatus comprises at least one fastening unit configured to mount on a hand-held power tool. The at least one fastening unit includes at least one holding element configured to be positioned on the hand-held power tool and at least one fastening element configured to exert a holding force on the at least one holding element. The at least one fastening unit also includes at least one movably mounted position fixing element configured to fix the at least one fastening element.

Abstract: The application concerns a support structure for power electronics, comprising a holder for the insertion of at least one power electronics module and an electrically conductive external geometry which surrounds the holder and has rounded corners and edges with a radius of curvature which is greater than a predetermined minimum radius.

Abstract: A single-chain insulin analogue containing a basic side chain at position A8 (Arginine, Histidine, Lysine, or Ornithine), a basic side chain at position B29 (Arginine, Histidine, Lysine, or Ornithine), and a foreshortened C-domain of length 6-11 residues is provided. Residues C1 and C2 of the C-domain have a net negative charge of ?1 or ?2; C3 is chosen from a group consisting of Gly, Ala, Pro, or Ser; and the remaining C-domain segment is successively derived from the C-domain of IGF-II (RRSR (SEQ ID NO: 18), SRRSR (SEQ ID NO: 17), VSRRSR (SEQ ID NO: 16), RVSRRSR (SEQ ID NO: 15), or SRVSRRSR (SEQ ID NO: 13)). A method of treating a patient with diabetes mellitus or obesity comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient.

Abstract: A temperature control device for temperature control of a steering device, characterized in that the temperature control device has at least one heat-conducting device, at least one thermoelectric device, and at least one fluid transport apparatus.

Abstract: A method for constructing an interactive database query interface. The method includes receiving a data structure including a search category for a consumable substance, an array of attributes associated with the search category, and range of values of the attributes. Each of the attributes indicates a physiological effect caused by ingesting the consumable substance. The range of values indicates intensity levels of the physiological effect. The method further includes dividing a graphical user interface in a plurality of sub-regions, and assigning a graphical representation in the graphical user interface with the search category and each of the plurality of sub-regions in the graphical user interface with one of the attributes in the array. The method further includes providing the graphical representation in the graphical user interface, where each of the plurality of attributes is displayed within the assigned sub-region of the graphical user interface.

Abstract: A pharmaceutical formulation comprises insulin having a variant insulin B-chain polypeptide containing an ortho-monofluoro-Phenylalanine substitution at position B24 in combination with a substitution of an amino acid containing an acidic side chain at position B10, allowing the insulin to be present at a concentration of between 0.6 mM and 3.0 mM. The formulation may optionally be devoid of zinc. Amino-acid substitutions at one or more of positions B3, B28, and B29 may additionally be present. The variant B-chain polypeptide may be a portion of a proinsulin analog or single-chain insulin analog. The insulin analog may be an analog of a mammalian insulin, such as human insulin. A method of lowering the blood sugar of a patient comprises administering a physiologically effective amount of the insulin analog or a physiologically acceptable salt thereof to the patient.

Abstract: A two-chain insulin analogue contains an A chain modified by (i) a monomeric glucose-binding element at or near its N terminus and (ii) a B chain modified by at or near its C terminus by an element that reversibly binds to the monomeric glucose-binding element such that this linkage is displaceable by glucose. The monomeric glucose-binding element may be phenylboronic acid derivative (optionally halogenated). The B chain may be modified by a diol-containing element derived from a monosaccharide, disaccharide or oligosaccharide, a non-saccharide diol-containing moiety or a ?-hydroxycarboxylate-containing moiety. The analogue can be manufactured by trypsin-mediated semi-synthesis. Formulations can be at strengths U-10 to U-1000 in soluble solutions at pH 7.0-8.0 with or without zinc ions at a molar ratio of 0.0-3.0 ions per insulin analogue monomer.

Abstract: The present invention provides rapid-acting insulin and insulin analog formulations. The invention further provides delivery devices, particularly infusion sets, which allow for the rapid absorption of insulin and insulin analogs, as well as other active agents. Methods of using the insulin and insulin analog formulations as well as the insulin delivery devices for treating subjects with diabetes mellitus are also provided.

Abstract: A contact holder device for a hand-held power tool includes at least one main body that is disposed inside a housing unit of the hand-held power tool. The main body accommodates or fixes contact elements configured to transmit data signals and/or electrical energy. The main body has at least one disposition plane and at least one group of contact elements are disposed in the disposition plane. The main body has at least one further disposition plane and at least one further group of contact elements are disposed in the further disposition plane. The further disposition plane is disposed in an offset manner in relation to the disposition plane.

Abstract: The present disclosure relates to a spectrometric measuring device for a process measuring point including a housing, a radiation source arranged in the housing, a coupling and decoupling optical system to direct radiation from the radiation source into a measuring region and to couple measuring radiation from the measuring region into the housing, a spectrograph arranged in the housing and aligned such that the measuring radiation is detected by the spectrograph with a detector, an electronic device arranged in the housing and connected to the detector and configured to detect a spectrum from the spectrograph and to process it to determine a concentration of an analyte in the measuring medium or a value derived therefrom, and a connection connected to the housing for connecting the housing to a process container, wherein the measuring region is located within a volume of the process container, said volume containing the measuring medium.

Abstract: A two-chain insulin analogue contains Aspartic Acid at position B10 and penta-fluoro-Phenylalanine at position B24, optionally Histidine or Glutamic Acid at position A8, optionally additional substitutions or modifications at positions A13 and/or A14 and/or B28 and/or B29. The analogue may be an analogue of a mammalian insulin, such as human insulin, may optionally include (i) N-terminal deletion of one, two or three residues from the B chain, (ii) a mono-peptide or dipeptide C-terminal extension of the B-chain containing at least one acidic residue, and (iii) other modifications known in the art to enhance the stability of insulin. Fomulations of the above analogues at successive strengths U-100 to U-1000 in soluble solutions at least pH value in the range 7.0-8.0 in the absence or presence of zinc ions at a molar ratio of 0.00-0.10 zinc ions per insulin analogue monomer.

Abstract: A nickel-base superalloy is disclosed. The superally includes aluminum, cobalt, chromium, molybdenum, tantalum, titanium and tungsten, in addition to nickel, as alloy constituents, wherein rhenium can additionally be contained and the rhenium content is less than or equal to 2 wt. % and wherein the titanium content is greater than or equal to 1.5 wt. %. Further disclosed is a component made of the nickel-base superalloy.

Abstract: A pharmaceutical formulation comprises an insulin analogue or a physiologically acceptable salt thereof, wherein the insulin analogue or a physiologically acceptable salt thereof contains an insulin A-chain sequence that contains paired Histidine substitutions at A4 and A8, and optionally a substitution at A21. The formulation further contains a pharmaceutically acceptable buffer containing at least about 4 zinc ions per 6 insulin analogue molecules. The formulation forms a long-acting zinc-dependent subcutaneous depot upon subcutaneous injection. In a zinc-free formulation, the insulin analogue monomer exhibits decreased affinity for the Insulin-like Growth Factor receptor and at least 20% of the affinity for the insulin receptor of the same species, in comparison to an otherwise identical insulin or insulin analogue that does not contain the HisA4 and HisA8 substitutions.